A Phase 4 interventional study of Luphere depot 3.75mg(Leuprolide acetate 3.75mg) in Central Precocious Puberty, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 4 Years to 9 Years. Per ClinicalTrials.gov, last updated 2014-08-04.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 4, Interventional, and Treatment
The purpose of this Clinical Trial was to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide acetate 3.75mg) in patients with precocious puberty.
75 studies on the registry are indexed under Puberty, Precocious; 19 are open to participants now.
This study's enrollment of 63 is close to the median of 64 across 47 interventional studies indexed under Puberty, Precocious.
Browse Puberty, Precocious studies →Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 196 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Luphere depot 3.75mg(Leuprolide acetate 3.75mg)
At 24 weeks, percentage of subjects with suppression of peak-stimulated Luteinizing Hormone (LH) concentrations
Time frame: At 24 weeks
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daewoong Pharmaceutical Co. LTD.